Clinical evidence from SLE patients has shown a significant increase in the expression of type 1 IFN signatures.164 Recently, Anifrolumab, a human monoclonal antibody that targets IFNAR1 to inhibit the biological function of all type 1 IFNs, has received approval for the treatment of moderate to severe SLE.165 Clinical trials have consistently demonstrated that Anifrolumab provides various clinical benefits, including reduced disease activity, decreased usage of oral corticosteroids, and fewer annual flares.144,166,167. The gene discussed is IFNAR1; the disease is systemic lupus erythematosus.